Literature DB >> 16850334

Nonmedical economic consequences attributable to visual impairment: a nation-wide approach in France.

Antoine Lafuma1, Antoine Brezin, Francis Fagnani, Viviane Mimaud, Mounir Mesbah, Gilles Berdeaux.   

Abstract

The nonmedical costs of visual impairment are crucial when allocating resources for prevention or treatment programs. Were analyzed the data from two representative nationwide French surveys aimed at documenting impairments that included 14,603 subjects living in institutions and 16,945 in the community. Three groups were identified: blind (light perception), low vision (loss of shape perception, LV), and controls. Item consumption was standardized on confounding factors using logistic regression. Costs attributable to visual impairment were estimated from control subjects. National nonmedical costs due to visual impairment were euro 9,806 million, arising mostly from LV (euro 8,735 million). The annual average cost/subject was euro 7,242 for LV and euro 15,679 for blindness. Loss of family income was euro 4,552 million, the burden on the caregiver euro 2,525 million, paid assistance euro 2,025 million, social allowances euro 0,942 million, and unmet needs euro 5,553 million. Resource allocation strategies aimed at controlling visual impairment should cover all relevant economic dimensions, including nonmedical items.

Entities:  

Mesh:

Year:  2006        PMID: 16850334     DOI: 10.1007/s10198-006-0346-1

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN: 1618-7598


  8 in total

Review 1.  Cost effectiveness of treatments for wet age-related macular degeneration.

Authors:  Paul Mitchell; Lieven Annemans; Richard White; Meghan Gallagher; Simu Thomas
Journal:  Pharmacoeconomics       Date:  2011-02       Impact factor: 4.981

2.  Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland.

Authors:  Arjun Bhadhuri; Daniel Dröschel; Mike Guldimann; Claudia Jetschgo; Judit Banhazi; Matthias Schwenkglenks; C Simone Sutherland
Journal:  BMC Health Serv Res       Date:  2022-06-28       Impact factor: 2.908

3.  Cost of cataract surgery after implantation of three intraocular lenses.

Authors:  Catherine Boureau; Antoine Lafuma; Viviane Jeanbat; Andrew F Smith; Gilles Berdeaux
Journal:  Clin Ophthalmol       Date:  2009-06-02

4.  Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.

Authors:  Francesco Bandello; Albert Augustin; José-Alain Sahel; Hicham Benhaddi; Cristina Negrini; Klaus Hieke; Gilles H Berdeaux
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

5.  The economic burden of visual impairment and blindness: a systematic review.

Authors:  Juliane Köberlein; Karolina Beifus; Corinna Schaffert; Robert P Finger
Journal:  BMJ Open       Date:  2013-11-07       Impact factor: 2.692

6.  The Cost of Blindness in the Republic of Ireland 2010-2020.

Authors:  D Green; G Ducorroy; E McElnea; A Naughton; A Skelly; C O'Neill; D Kenny; D Keegan
Journal:  J Ophthalmol       Date:  2016-02-15       Impact factor: 1.909

7.  Large-scale assessment of needs in low vision individuals using the Aira assistive technology.

Authors:  Brian J Nguyen; William S Chen; Allison J Chen; Andrew Utt; Emily Hill; Ryan Apgar; Daniel L Chao
Journal:  Clin Ophthalmol       Date:  2019-09-20

8.  Development of the conceptual framework for the Eye-Drop Satisfaction Questionnaire (EDSQ) in glaucoma using a qualitative study.

Authors:  Jean-Philippe Nordmann; Philippe Denis; Marc Vigneux; Elyse Trudeau; Isabelle Guillemin; Gilles Berdeaux
Journal:  BMC Health Serv Res       Date:  2007-08-06       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.